Predicting tuberculosis treatment outcome in a low-incidence area

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 12, 2008, Pages 1441-1448

  Baussano, Iacopo ^a,b,e   Pivetta, E ^c   Vizzini, L ^c   Abbona, F ^d   Bugiani, M ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CPA ASL 4   (Italy)

^e CPO Piemonte   (Italy)

Author keywords

Cohort analysis; Epidemiology; Surveillance; Treatment; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HOSPITAL PATIENT; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTPATIENT CARE; PRIORITY JOURNAL; SEX DIFFERENCE; SHORT COURSE THERAPY; TREATMENT OUTCOME;

COHORT STUDIES; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; MALE; SEX FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 58049197834     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
2. Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367: 938-940.
3. Veen J, Raviglione M, Rieder H L, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a working group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998; 12: 505-510.
4. Broekmans J F, Migliori G B, Rieder H L, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
5. Faggiano F, Vigna-Taglianti F D, Versino E, Salamina G, Bugiani M. Tuberculosis incidence in Turin, Italy, 1973-1999. Int J Tuberc Lung Dis 2004; 8: 171-179.
6. Matteelli A, Casalini C, Raviglione M C, et al. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. Am J Respir Crit Care Med 2000; 162: 1653-1655.
7. Baussano I, Bugiani M, Gregori D, Pasqualini C, Demicheli V, Merietti F. Impact of immigration and HIV infection on tuberculosis incidence in an area of low tuberculosis prevalence. Epidemiol Infect 2006; 134: 1353-1359.
8. Assessorato Sanità, Assistenza Direzione Sanità Pubblica Settore Igiene e Sanità Pubblica. Tuberculosis prevention and control of tuberculosis among humans. Operational protocols. Regione Piemonte, Torino, Italia: Assessorato Sanità, 2000. [Italian]
9. Hopewell P C, Pai M, Maher D, Uplekar M, Raviglione M C. International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710-725.
10. Migliori G B, Hopewell P C, Blasi F, Spanevello A, Raviglione M C. Improving the TB case management: the International Standards for Tuberculosis Care. Eur Respir J 2006; 28: 687-690.
11. Caiazzo A, Cardano M, Cois E, et al. [Inequalities in health in Italy]. Epidemiol Prev 2004; 28: i-ix, 1-161. [Italian]
12. Sabbatani S, Baldi E, Manfredi R. Time trends in health care needs of non-EU citizens from developing countries, admitted to a general hospital in northern Italy. Infez Med 2007; 15: 242-249.
13. Faustini A, Hall A J, Perucci C A. Tuberculosis treatment outcomes in Europe: a systematic review. Eur Respir J 2005; 26: 503-510.
14. Efron B, Tibshirani R, Robert J. An introduction to the bootstrap. London, UK: Chapman & Hall, 1993.
15. Hanley J A, McNeil B J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
16. R Development Core Team R. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2006. http://www.R-project.org Accessed August 2008.
17. Harrell F E Jr. Design: design package. R package version 2.0-12. Nashville, TN, USA: Department of Biostatistics, Vanderbilt University, 2007. http://biostat.mc.vanderbilt.edu/s/Design Accessed August 2007.
18. Falzon D, Le Strat Y, Belghiti F, Infuso A. Exploring the determinants of treatment success for tuberculosis cases in Europe. Int J Tuberc Lung Dis 2005; 9: 1224-1229.
19. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. WHO report 2003. WHO/CDS/TB 2003/313. Geneva, Switzerland: WHO, 2003.
20. Borgdorff M W, Veen J, Kalisvaart N A, Broekmans J F, Nagelkerke N J. Defaulting from tuberculosis treatment in The Netherlands: rates, risk factors and trend in the period 1993-1997. Eur Respir J 2000; 16: 209-213.
21. Farah M G, Tverdal A, Steen T W, Heldal E, Brantsaeter A B, Bjune G. Treatment outcome of new culture-positive pulmonary tuberculosis in Norway. BMC Public Health 2005; 5: 14.
22. Helbling P, Medinger C, Altpeter E, Raeber P A, Beeli D, Zellweger J P. Outcome of treatment of pulmonary tuberculosis in Switzerland in 1996. Swiss Med Wkly 2002; 132: 517-522.
23. Concato J, Rom W N. Endemic tuberculosis among homeless men in New York City. Arch Intern Med 1994; 154: 2069-2073.
24. Burman W J, Cohn D L, Rietmeijer C A, Judson F N, Sbarbaro J A, Reves R R. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111: 1168-1173.
25. Martens W H. A review of physical and mental health in homeless persons. Public Health Rev 2001; 29: 13-33.
26. Falzon D, Scholten J, Infuso A. Tuberculosis outcome monitoring - is it time to update European recommendations? Euro Surveill 2006; 11: 20-25.
27. World Health Organisation. Forty-fourth World Health Assembly, Geneva, 6-16 May 1991. WHA44/1991/REC/1. Geneva, Switzerland: WHO, 1991.
28. Munsiff S S, Li J, Cook S V, et al. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect Dis 2006; 42: 1702-1710.
29. Ambrosetti M, Besozzi G, Codecasa L R, et al. The Italian AIPO study on tuberculosis treatment results, report 1995. National AIPO 'Tuberculosis' Study Group. Monaldi Arch Chest Dis 1999; 54: 49-54.
30. Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano. Linee-guida per il controllo della malattia tubercolare, su proposta del Ministro della Sanità, ai sensi dell'art. 115, comma 1, lettera b), del decreto legislativo 31 marzo 1998, n. 112. http://epidem.asl20.piemonte.it/uploads/documenti361_DL31_03_98.pdf Accessed August 2007.
31. Volmink J G, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2006; 2: CD003343.
32. Macq J C, Theobald S, Dick J, Dembele M. An exploration of the concept of directly observed treatment (DOT) for tuberculosis patients: from a uniform to a customised approach. Int J Tuberc Lung Dis 2003; 7: 103-109.
33. Deruaz J, Zellweger J P. Directly observed therapy for tuberculosis in a low prevalence region: first experience at the tuberculosis dispensary in Lausanne. Swiss Med Wkly 2004; 134: 552-558.
34. Jasmer R M, Snyder D C, Saukkonen J J, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. Clin Infect Dis 2004; 38: 363-369.
35. Ormerod L P, Horsfield N, Green R M. Tuberculosis treatment outcome monitoring: Blackburn 1988-2000. Int J Tuberc Lung Dis 2002; 6: 662-665.
36. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
37. Cummings K C, Mohle-Boetani J, Royce S E, Chin D P. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 1998; 157: 1249-1252.
38. Gasner M R, Maw K L, Feldman G E, Fujiwara P I, Frieden T R. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med 1999; 340: 359-366.